Monday, June 30, 2025 6/30/2025

Mechanism-guided drug repurposing for host-directed therapy of infectious diseases using interpretable and integrative ML

Award Number: R21AI169301
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/09/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2024

Group Awards By:

View Award Description

Mechanism-guided drug repurposing for host-directed therapy of infectious diseases using interpretable and integrative ML - ABSTRACT Our ability to treat infectious diseases is impeded by two major problems. One is the rapid increase of antimicrobial resistance, and the other is the prohibitive cost and time required for discovering new drugs. A potential approach to overcome these problems is to focus on repurposing existing drugs for host-directed therapy. However, this is an emerging application area. While several studies have used this broad approach to find drug candidates for specific viruses and bacterial infections, there is a dearth of systematic computational frameworks that can be used to repurpose drugs for any infectious disease, especially ones that focus on drug and disease mechanisms rather than individual drug and target properties. Also missing are frameworks that can leverage the massive amounts of data and knowledge available for non-infectious diseases to tackle infectious disease treatment. In this project, we will develop an integrative framework that uses mechanism- guided, interpretable machine learning (ML) models to repurpose drugs to bolster host response to infection. Our framework leverages massive transcriptome data collections and genome-scale human gene interaction networks; these are two complementary sources of information about molecular mechanisms relevant for this repurposing effort. It also uses data and knowledge about hundreds of non-infectious diseases and thousands of small molecules (including FDA-approved drugs) to create numerous repurposing opportunities. Requiring only host transcriptome data in response to infection, our general-purpose ML framework will be applicable to new, emerging, and understudied infectious diseases. This project will also result in high-confidence drug candidates for several infectious diseases along with mechanistic insights into new avenues for host-directed therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	THE REGENTS OF THE UNIVERSITY OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Allergy and Infectious Diseases Research	001	2	2/2/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$732
2024	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Allergy and Infectious Diseases Research	000	1	2/2/2024	NEW	-$732
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $181,773 )
2023	2023	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Allergy and Infectious Diseases Research	002	3	4/12/2023	NON-COMPETING CONTINUATION	$181,773
2023	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Allergy and Infectious Diseases Research	000	1	11/30/2022	NEW	-$221,694
2023	2022	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Allergy and Infectious Diseases Research	001	2	11/30/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$221,694
														Subtotal = $181,773

Issue Date FY: 2022 ( Subtotal = $222,426 )
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Allergy and Infectious Diseases Research	000	1	5/9/2022	NEW	$222,426
														Subtotal = $222,426

Grand Total All Awards = $404,199

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanism-guided drug repurposing for host-directed therapy of infectious diseases using interpretable and integrative ML

Award Number: R21AI169301

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/09/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer